BCLI (Brainstorm Cell Therapeutics) Short Ratio


BCLI Brainstorm Cell Therapeutics Inc BCLI
28 GF Score
Price $1.01
! 2 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BCLI
28GF Score
Brainstorm Cell Therapeutics Inc BCLI
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics Business Description

Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for BCLI

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price